Lu J. and colleagues designed a hetero-bifunctional proteolysis targeting chimera (PROTAC), ARV-825, by connecting the small-molecule BRD4 binding moiety OTX015 to the E3 ligase cereblon binding moiety of pomalidomide that recruits BRD4 and BRD2 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and BRD2, effective suppression of c-MYC signaling, inhibition of cell proliferation and apoptosis induction in BL in vitro [411]. The gene discussed is BRD4; the disease is Burkitt lymphoma.